SCHEMBL4338100

SCHEMBL4338100

N#Cc1cc(C=NNC(N)=S)ccc1N1CCN(Cc2cccc(Cl)c2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.43
ACHE P22303 1/20 0.42
CHRM4 P08173 1/20 0.42
POLB P06746 1/20 0.42
SIGMAR1 Q99720 1/20 0.42
ALOX12 P18054 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
HCRTR1 O43613 1/20 0.42
ALDH1A1 P00352 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
KMT2A Q03164 1/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
DRD2 P14416 1/20 0.40
DRD4 P21917 1/20 0.40
DRD3 P35462 1/20 0.40
MAOB P27338 1/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4338092 1.00 PKM (0.43) PKMACHECHRM4POLBSIGMAR1
SCHEMBL4327308 0.93 ACHE (0.49) ACHECHRM4POLBALDH1A1KDM4E
SCHEMBL4327302 0.93 ACHE (0.49) ACHECHRM4POLBALDH1A1KDM4E
SCHEMBL4331921 0.90 PKM (0.46) PKMACHEPOLBSIGMAR1ALOX12
SCHEMBL4331926 0.90 PKM (0.46) PKMACHEPOLBSIGMAR1ALOX12
SCHEMBL4326166 0.89 ACHE (0.47) ACHECHRM4POLBALDH1A1
SCHEMBL4326161 0.89 ACHE (0.47) ACHECHRM4POLBALDH1A1
SCHEMBL4329600 0.89 TYR (0.48) PKMACHEPOLBSIGMAR1ALOX12
SCHEMBL4329609 0.89 TYR (0.48) PKMACHEPOLBSIGMAR1ALOX12
SCHEMBL4335100 0.87 PKM (0.48) PKMACHEPOLBSIGMAR1ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 PKM 4105/4885ACHE 2128/4885CHRM4 2972/4885
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 PKM 4038/4885ACHE 1897/4885CHRM4 2366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.